Home/Pipeline/VisAcT (18F-AraG) Imaging in NSCLC

VisAcT (18F-AraG) Imaging in NSCLC

Non-Small Cell Lung Cancer

Phase 2Active

Key Facts

Indication

Non-Small Cell Lung Cancer

Phase

Phase 2

Status

Active

Company

CellSight Technologies

About CellSight Technologies

CellSight Technologies is a private, pre-revenue biotech focused on a diagnostic imaging platform for the immune system. Its core technology, the VisAcT (18F-AraG) PET tracer, selectively accumulates in activated T cells, providing a non-invasive window into immune activity. The company is actively advancing its platform through multiple investigator-sponsored clinical trials, primarily in non-small cell lung cancer (NSCLC), with the goal of guiding and improving immunotherapy outcomes. Its long-term vision extends to neurodegenerative and cardiac diseases where immune activation plays a key role.

View full company profile

Therapeutic Areas

Oncology Neurology Cardiology Autoimmune Diseases

Other Non-Small Cell Lung Cancer Drugs

Drug	Company	Phase	Status
CM24	Purple Biotech	Phase 2	Active
Pepinemab (VX15/2503)	Vaccinex	Phase 1b/2	Completed
GC-001	Genocury Biotech	Preclinical	Active
Immunomodulator Platform	OmniCyte	Research	Active
VNX-208	Vironexis Biotherapeutics	Preclinical	Active
AIC100	AffyImmune Therapeutics	Pre-clinical/Planned	Active
Lung (NSCLC) PD-L1	Mindpeak	Commercial	Active
Tiragolumab	Chugai Pharmaceutical	Phase III	Active
SHR-1701	Jiangsu Hengrui Medicine	Phase II/III	Active
Acasunlimab (DuoBody-PD-L1x4-1BB)	Genmab	Phase 2/3	Active
VAC2	Lineage Cell Therapeutics	Phase 1	Active